Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 20:2018:7938130.
doi: 10.1155/2018/7938130. eCollection 2018.

Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso

Salam Sawadogo  1   2 , Koumpingnin Nebie  1   2 , Tieba Millogo  3 , Sonia Sontie  2 , Ashmed Nana  2 , Honorine Dahourou  2 , Dieudonné Yentema Yonli  2 , Jean-Baptiste Tapko  4 , Jean-Claude Faber  5 , Eléonore Kafando  1 , Véronique Deneys  6
Affiliations

Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso

Salam Sawadogo et al. Adv Hematol. .

Abstract

Traceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over the 6-year postpilot phase. A cross-sectional study including all blood units ordered between 2010 and 2015 has been conducted in public and private health care facilities supplied with blood products by the transfusion center of Bobo-Dioulasso. The complete traceability was possible for 83.5% of blood units delivered. Adverse reactions were reported in 107 cases representing 2.1/1,000 blood units per annum. Transfusions of wrong blood to wrong patient were reported in 13 cases. Our study shows that the haemovigilance system in Burkina Faso must be improved. Healthcare workers have to be sensitized on how traceability and haemovigilance could impact the quality of care provided to patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of blood units plotted compared to number of untraceable blood units per (a) year of delivery, (b) type of hospital, (c) clinical ward, and (d) type of blood products at the Regional Blood Transfusion Center of Bobo-Dioulasso from 2010 to 2015. Tea Hosp = Teaching Hospital; Dist Hospt = District Hospital; Priv Heal Facil = Private Health Facilities; Gyn-Obs = Gynaecology-Obstetrics; Surg = Surgery; Paed = Paediatrics; Med = Medicine; RBCs = Red blood cells; FFP = Frozen fresh plasma; PCs = Platelet concentrates.
Figure 2
Figure 2
Incidence of adverse reactions reported to the Regional Blood Transfusion Center of Bobo-Dioulasso from 2010 to 2015, Burkina Faso.
Figure 3
Figure 3
Types of adverse reactions reported to the Regional Blood Transfusion Center of Bobo-Dioulasso from 2010 to 2015, Burkina Faso.
See this image and copyright information in PMC

References

    1. Somagari D. R., Sriram C. S., Rachamalla C. K., et al. Haemovigilance study at a tertiary care hospital in the north-east of India. ISBT Science Series. 2015;10(2):61–64. doi: 10.1111/voxs.12182. - DOI
    1. Natukunda B., Schonewille H., Smit Sibinga C. T. Assessment of the clinical transfusion practice at a regional referral hospital in Uganda. Transfusion Medicine. 2010;20(3):134–139. doi: 10.1111/j.1365-3148.2010.00992.x. - DOI - PubMed
    1. Pélissier E., Nguyen L. Traçabilité des produits sanguins labiles: définition, réglementation, bilan et perspectives. Transfusion Clinique et Biologique. 2000;7(suppl 1):72–74. doi: 10.1016/S1246-7820(00)80021-X. - DOI - PubMed
    1. Ministère de la santé et de l'action humanitaire. Loi no 93-5 du 4 janvier 1993 relative à la sécurité en matière de transfusion sanguine et de médicament. Journal officiel français. 1993:237–245.
    1. Ingrand P., Salmi L., Benz-Lemoine E., Dupuis M. Évaluation de la traçabilité effective des produits sanguins labiles à partir des dossiers médicaux. Transfusion Clinique et Biologique. 1998;5(6):397–407. doi: 10.1016/S1246-7820(99)80004-4. - DOI - PubMed

LinkOut - more resources